Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (17218)	5/27/2006 1:55:19 PM
From: bob zagorin	Respond to of 17367

XOMA Deal Worth Up to $75 Million Friday May 26, 4:39 pm ET Xoma Getting Funding, Milestone Payments Up to $75 Million in Schering-Plough Deal BERKELEY, Calif. (AP) -- Drug research company XOMA Ltd. could see funding and milestone payments between $25 million and $75 million as part of a collaboration with Schering-Plough Corp. to develop monoclonal antibodies for disease diagnosis and treatment. Schering-Plough will fund XOMA's research and development, make upfront and milestone payments, and pay royalties to XOMA on future sales of a treatment. The deal was announced Tuesday, and posted on the Securities and Exchange Commission's Web site on Friday. The companies did not specify the diseases for which the antibodies will be developed. Xoma shares rose 6 cents, or 3.5 percent, to close at $1.84 on the Nasdaq, then tacked on another 5 cents in after-hours electronic trading on the Inet. Schering shares closed up 7 cents to $19.37 on the New York Stock Exchange.